Page 2,673«..1020..2,6722,6732,6742,675..2,6802,690..»

Fresh cell therapy promises better health, sex and more

Posted: August 14, 2012 at 9:13 pm

MANILA, Philippines Celebrity hairstylist Ricky Reyes, talent manager and host Lolit Solis, actress Lorna Tolentino and even former President Joseph Estrada are only among the prominent Filipinos who swear by the healing effects of fresh cell therapy, which involves the injection of live animal cells into the body.

Reyes, who used to suffer from a rare disease which he called reading eye epilepsy, said he went to Germany last June for fresh cell therapy.

After a number of sessions, the celebrity hairstylist can now read newspapers without suffering a seizure.

It was gone immediately, he said. Pati arthritis ko. Naalis yung sakit, tapos gaganda at babata ka pa.

Solis, 65, had fresh cell therapy after experiencing knee pain, and 75-year-old Estrada opted to undergo the procedure in Germany to keep healthy.

Before them, several other well-known figures worldwide are said to have tried fresh cell treatments, among them the late English actor Charlie Chaplin.

So how is this procedure done? Dr. Robert Janson-Muller, who runs a fresh cell therapy clinic in Germany, is in town to give Filipinos the lowdown on this decades-long treatment.

Not stem cell treatment

Before starting his lecture for members of the local media on Tuesday, Janson-Muller made it clear that fresh cell therapy is different from the now controversial stem cell treatment, which aims to replace damaged organs in the body or create one from scratch.

He stressed that his methods, which do not promise miracles, have been proven effective by his predecessors for the past 60 years.

See the original post:
Fresh cell therapy promises better health, sex and more

Posted in Cell Therapy | Comments Off on Fresh cell therapy promises better health, sex and more

Verastem Reports Second Quarter 2012 Financial and Corporate Results

Posted: August 13, 2012 at 10:21 pm

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Verastem, Inc., (VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, today reported financial results for the quarter ended June 30, 2012, and also commented on certain corporate accomplishments and plans.

We made significant advances in our therapeutic programs during the second quarter, said Christoph Westphal, M.D., Ph.D., Chairman, President and Chief Executive Officer of Verastem. The acquisition of the Phase 2-ready focal adhesion kinase inhibitors from Pfizer accelerates this key cancer stem cell-targeting program by approximately 12-18 months, and we are now positioned to initiate a potential registration study in mesothelioma next year.

Recent Accomplishments

Our significant recent accomplishments include the following:

Focal Adhesion Kinase (FAK) Inhibition

Dual PI3K/mTOR Inhibition

Corporate

Second Quarter 2012 Financial Results

As of June 30, 2012, Verastem had cash, cash equivalents and investments of $104.3 million compared to $56.8 million on December 31, 2011.

Read more:
Verastem Reports Second Quarter 2012 Financial and Corporate Results

Posted in Stem Cell Videos | Comments Off on Verastem Reports Second Quarter 2012 Financial and Corporate Results

Human embryos frozen for 18 years yield viable stem cells suitable for biomedical research

Posted: August 13, 2012 at 10:21 pm

Public release date: 13-Aug-2012 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, August 13, 2012Even after being frozen for 18 years, human embryos can be thawed, grown in the laboratory, and successfully induced to produce human embryonic stem (ES) cells, which represent a valuable resource for drug screening and medical research. Prolonged embryonic cryopreservation as an alternative source of ES cells is the focus of an article in BioResearch Open Access, a new bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc. The article is available free online at the BioResearch Open Access website.

Kamthorn Pruksananonda and coauthors from Chulalongkorn University and Chulalongkorn Memorial Hospital, Bangkok, Thailand, demonstrated that ES cells derived from frozen embryos have a similar ability to differentiate into multiple cell typesa characteristic known as pluripotencyas do ES cells derived from fresh embryos. They present their findings in the article "Eighteen-Year Cryopreservation Does Not Negatively Affect the Pluripotency of Human Embryos: Evidence from Embryonic Stem Cell Derivation."

"The importance of this study is that it identifies an alternative source for generating new embryonic stem lines, using embryos that have been in long-term storage," says Editor-in-Chief Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland.

###

About the Journal

BioResearch Open Access is a bimonthly peer-reviewed open access journal that provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMedCentral. All journal content is available online at the BioResearch Open Access website.

About the Publisher

Mary Ann Liebert, Inc., is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Tissue Engineering, Stem Cells and Development, Human Gene Therapy and HGT Methods, and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available at the Mary Ann Liebert, Inc. website.

See the article here:
Human embryos frozen for 18 years yield viable stem cells suitable for biomedical research

Posted in Stem Cell Videos | Comments Off on Human embryos frozen for 18 years yield viable stem cells suitable for biomedical research

Stemgent rakes in $11M, largest round to date

Posted: August 13, 2012 at 10:20 pm

Cambridge stem cell research company Stemgent Inc. has taken $11.3 million in equity, the largest round to date for the four-and-a-half year old company, according to federal filings.

The 40-plus employee company, headquartered in Kendall Square with another research and development site in San Diego, Calif., has filed for more than $40 million in debt and equity investment to date. Most recent is a $6.3 million round in February, which came from eight investors who were not listed on the filing. At the time, CEO Ian Ratcliffe told Mass High Tech that the company would use the new funding to expand its licensed intellectual property around stem cell reagents, as well as expanding its existing operations and product lines.

The current filing indicates that the $11.3 million comes from eight backers, with related persons listed as board members Stefan Miltenyi, founder of German biotech; Harold Werner and Augustine Lawlor of HealthCare Ventures LLC of Cambridge; and Ralph Christofferson of Morganthaler Partners of Ohio. No one from the company was available for comment Monday.

The companys mission is to support cellular reprogramming research by producing products being designed by stem cell researchers. In January 2010, it launched a custom cell line generation service to provide companies with induced pluripotent stem cells - adult cells that have been genetically reprogrammed to an embryonic stem celllike state. Two months later, it launched Ubiquigent Ltd., a subsidiary based in Scotland which produces technology focused on the biology of the ubiquitin protesome pathway (UPP).

In June, Stemgent bought the human tissue business of the UKs Asterand Plc. for $9 million in cash.

Continue reading here:
Stemgent rakes in $11M, largest round to date

Posted in Stem Cell Research | Comments Off on Stemgent rakes in $11M, largest round to date

1DegreeBio Launches Online Resource for Stem Cell Researchers

Posted: August 13, 2012 at 10:20 pm

Toronto, ON (PRWEB) August 13, 2012

1DegreeBio Inc. today launched its Stem Cell Portal, where stem cell researchers can find antibodies and product data specific to their research. The portal also provides a venue where scientists can read and submit reviews of these products, and see quality ratings from the community. The portal is the second in a series of 1DegreeBio portals targeted at specific research areas which will be released in the coming year, and follows the June launch of the 1DegreeBio Epigenetics Portal.

1DegreeBio is the largest independent review website for custom research services, antibodies and related life science products.

Stem cells are an extremely promising avenue in medical research, with new breakthroughs every day, said Alex Hodgson, Managing Director, 1DegreeBio. 1DegreeBio is excited to provide a free, specialized resource to support stem cell researchers, and help them find the best products for their work.

Commercial antibodies are often an essential component in stem cell research, but inconsistency in antibody quality often slows the research process. The new 1DegreeBio Stem Cell Portal is designed to address this issue, as researchers can find validation data and community reviews of stem cell antibodies, helping them identify the right product for their experiments.

The commercial outcomes from large tax-payer investments in stem cell research are increasing steadily, says Dr. Rahul Sarugaser, Director of Business Development for the Centre for Commercialization of Regenerative Medicine. Open-access resources like the 1DegreeBio Stem Cell Portal provide great support for this rapidly-growing field.

Stem cell research has implications for a number of chronic diseases and conditions, such as cancer, spinal cord injury, heart disease and diabetes.

It is critical that scientists have the right tools to keep pushing our research forward efficiently, said Dr. Geneve Awong, a stem cell researcher at the University Health Network in Toronto and 1DegreeBio user. The 1DegreeBio Stem Cell Portal is an excellent resource that helps make that possible.

About 1DegreeBio Inc.

1DegreeBio.org is an independent product and service review site for life scientists, featuring the worlds largest antibody database. Listing more than 800,000 products and services from 400 providers, 1DegreeBio has all the information researchers need to find the right products and services for their research, including quality validation data, citations, user reviews and ratings. http://1degreebio.org

See the article here:
1DegreeBio Launches Online Resource for Stem Cell Researchers

Posted in Stem Cell Research | Comments Off on 1DegreeBio Launches Online Resource for Stem Cell Researchers

Verastem Reports Second Quarter 2012 Financial and Corporate Results

Posted: August 13, 2012 at 1:14 pm

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Verastem, Inc., (VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, today reported financial results for the quarter ended June 30, 2012, and also commented on certain corporate accomplishments and plans.

We made significant advances in our therapeutic programs during the second quarter, said Christoph Westphal, M.D., Ph.D., Chairman, President and Chief Executive Officer of Verastem. The acquisition of the Phase 2-ready focal adhesion kinase inhibitors from Pfizer accelerates this key cancer stem cell-targeting program by approximately 12-18 months, and we are now positioned to initiate a potential registration study in mesothelioma next year.

Recent Accomplishments

Our significant recent accomplishments include the following:

Focal Adhesion Kinase (FAK) Inhibition

Dual PI3K/mTOR Inhibition

Corporate

Second Quarter 2012 Financial Results

As of June 30, 2012, Verastem had cash, cash equivalents and investments of $104.3 million compared to $56.8 million on December 31, 2011.

Read the original:
Verastem Reports Second Quarter 2012 Financial and Corporate Results

Posted in Stem Cells | Comments Off on Verastem Reports Second Quarter 2012 Financial and Corporate Results

Biostem Medical Director, Dr. Marina Pizarro Performs First Biostem Method(TM) of Hair Re-Growth Procedures at Orlando …

Posted: August 13, 2012 at 1:14 pm

CLEARWATER, FL--(Marketwire -08/13/12)- Biostem U.S., Corporation (HAIR) (HAIR) (Biostem, the Company) is a fully reporting public company in the stem cell regenerative medicine sciences sector. President, John Satino announced today that the Pizarro Hair Restoration Clinic in Orlando, Florida is now equipped and ready to begin offering The Biostem Method of hair re-growth using the patient's own adult cells in a minimally invasive, painless procedure. In addition, Biostem Medical Director and Trainer, Dr. Marina Pizarro is ready to offer onsite training to new Biostem affiliates.

According to Satino, "This week, Dr. Pizarro treated her first two patients using The Biostem Method of hair re-growth in her Orlando office. This paves the way for Biostem to start offering affiliate agreements throughout the country in response to the many inquiries from physicians who want to offer this transplant alternative to their patients. We are making plans to open affiliate offices in major cities soon, after which we will expand the services to rural and international locations focusing first on Europe and Asia."

As a side note, Satino stated that, "While the industry typically sees more males requesting hair transplant for hair re-growth solutions, it is interesting that the first two treatments Dr. Pizarro performed were on women. Statistics do show that women suffer hair loss in significant numbers, yet are less likely to go through the transplant procedure. The Biostem Method finally offers women as well as men, a viable and proven alternative."

About Biostem U.S. Corporation Biostem U.S., Corporation (HAIR) is a fully reporting Nevada corporation with offices in Clearwater, Florida. Biostem U.S. is a technology licensing company with proprietary technology centered on providing hair re-growth using human stem cells. The company also intends to train and license selected physicians to provide Regenerative Cellular Therapy treatments to assist the body's natural approach to healing tendons, ligaments, joints and muscle injuries by using the patient's own stem cells. Biostem U.S. is seeking to expand its operations worldwide through licensing of its proprietary technology and acquisition of existing stem cell related facilities. The company's goal is to operate in the international biotech market, focusing on the rapidly growing regenerative medicine field, using ethically sourced adult stem cells to improve the quality and longevity of life for all mankind.

The company's Board of Directors is headed by Chairman, Scott Crutchfield, who also acts as Senior Vice President of World Wide Operations for Crocs, Inc. (CROX) and includes Crocs, Inc. original member, Steve Beck.

More information on Biostem U.S., Corporation can be obtained through http://www.biostemus.com or by contacting Fox Communications Group at 310-974-6821.

See the rest here:
Biostem Medical Director, Dr. Marina Pizarro Performs First Biostem Method(TM) of Hair Re-Growth Procedures at Orlando ...

Posted in Regenerative Medicine | Comments Off on Biostem Medical Director, Dr. Marina Pizarro Performs First Biostem Method(TM) of Hair Re-Growth Procedures at Orlando …

Everyone At Risk From Mad Cow Disease

Posted: August 12, 2012 at 3:52 pm

By John von Radowitz, Science Correspondent, PA News

No one is immune to the human form of mad cow disease, variant CJD, new research suggests today.

Some people whose genetic make-up normally acts as a barrier against infection may ultimately develop a different and so-far unrecognised type of disease, it is claimed.

Scientists have shown that individuals with a pair of genes known as MM about a third of the population acquire vCJD relatively easily.

No one with a different paring, VV, has been known to suffer the disease.

Then in August it emerged that a patient from a mixed MV genetic group had been infected with vCJD from contaminated blood, without showing any symptoms. Just over half the population has the MV pairing.

The news sparked fears of a mad cow disease timebomb in the population, with thousands of people unwittingly carrying the brain disease on a long incubation fuse. Read more…

Source:
http://feeds.feedburner.com/integratedmedicine

Posted in Integrative Medicine | Comments Off on Everyone At Risk From Mad Cow Disease

Is the cell therapy sector outperforming the major indices?

Posted: August 12, 2012 at 3:52 pm


So here's what I did today.  I built a portfolio of public companies focused exclusively or predominately in the cell therapy space.  I excluded any companies that are in the sector but their products/services constitute less than a significant majority of their revenue and/or expenses.  The portfolio sits at 29 companies.  Here's the list:


Here's how the portfolio performs against the Dow Jones, Standard and Poor's, and NASDAQ indices so far this year.


When looking at the period 1 January 2012 to 10 August 2012, the cell therapy portfolio is up 42%, Dow Jones up 8%, Standard and Poor's up 12% and NASDAQ up 16%.

In the context of how much we hear about how harsh this sector is or has been on investors, I found today's analysis interesting and, honestly, pleasantly surprising.

This snapshot is useful but has its limitations. I'm relying on Google Finance for accuracy of the information provided.  Do your own due diligence. Invest accordingly.  I hope this helps.

--Lee

This snapshot has been brought to you by Cell Therapy Group: all cell therapy, all the time! 🙂

Source:
http://feeds.feedburner.com/CellTherapyBlog

Posted in Regenerative Medicine | Comments Off on Is the cell therapy sector outperforming the major indices?

Researcher Alert: Opportunity for Fresh Appeal in $243 Million Disease Team Round

Posted: August 12, 2012 at 3:52 pm


A tiny opening exists for scientists
who failed to win approval last month of their bids for $20 million
research awards from the California stem cell agency.

On July 26, the agency's governing
board okayed $151 million for eight scientists during a day filled
with emotional testimony from patients, as well as appeals by
researchers seeking reconsideration of rejection by grant reviewers
at the California Institute for Regenerative Medicine. The board also
asked reviewers to take a fresh look at five applications in its signature disease team round.
However, the board failed to act on
eight applications, meaning that they are still pending. Normally the
board will approve -- as a group -- one set of applications. Then, at
the same meeting, it will vote to reject another set of applications.
On July 26, however, the hard-pressed directors late in the
afternoon lost the supermajority quorum (65 percent) required to do
business and adjourned without acting on all the applications.
This situation rarely occurs on award
rounds. In our recollection, it has happened only once before
although there may have been other occasions.
That leaves an opening for more
researchers to ask the board to act favorably at its Sept. 5-6 meeting in San Francisco on applications rejected by reviewers. Money
is available. The July 26 round was budgeted for $243 million.
At the meeting last month, discussion
by directors provided several clues to appropriate avenues for
reconsideration. They were interested in appeals, formally called
extraordinary petitions, that brought genuinely new information to
the table. Serious errors in the reviews – something more than
differences of opinion – were of interest. Wide variance in the
spread of scientific scores on specific applications, including the
preliminary scores, also triggered directors' interest.
Researchers considering appeals would
be well-advised to listen to the audiocast of the meeting to hear the
discussion of appeals. The transcript of the meeting also should be
posted soon on the CIRM website, probably this week. The transcript
can be found via this page when it is posted. The audiocast
instructions can be found on the July 26 meeting agenda.
(The best available information on the
CIRM web site shows a Sept. 5-6 governing board meeting. However,
that schedule also shows other two day meetings earlier this year,
which actually have turned out to be only one day.)

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Researcher Alert: Opportunity for Fresh Appeal in $243 Million Disease Team Round

Page 2,673«..1020..2,6722,6732,6742,675..2,6802,690..»